Didn’t even know I had this. I guess I didn’t need to buy the new publication of Teeka trillion dollar trade. This is the IPO he didn’t talk about EI.VENTURES
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Thank you for this information glove77. ei.ventures is engaged in psilocybin mushroom extract and mushroom based nutritional supplement
Ei.Ventures Inc.is a Hawaii based start-up company with the ambition to develop regulatory approved, plant-derived, psychoactive therapeutic treatment options and non-psychoactive nutritional supplements. It received patent and trademark for Psilly. Psilly is their exclusive botanical psilocybin-based therapeutic formulation which they want to bring to a pre-clinical and phase 1 trial. they focus on developing Botanical (all fungi and plant based) Psychedelic API and Therapeutics… instead of single molecule synthetic psilocybin (which is the focus of competitors like Compass and Cybin). the magic mushrooms contain several key compounds other than Psilocybin and Psilocin that suggest an “entourage effect” resulting synergy of compounds that creates a unique “psilocybin signature” and which they believe is potentially the best of breed.
what are the other 5 public companies here?
I assume Numinus is one of these (but this is a guess) beside Compass.
MYCOF buy up .75 LKYS buy up $1.50 PRXTF buy up .50 CLXP buy up$3.00 MNMD buy up $5.00 Numinus is LKYS.
LKYSF is Numinus Wellness
Thank you so much glove 77. Your the best! I purchased several thousand shares of MNMD “Mind Meds” at around .50 about a year ago. Did Teeka mention how high he expects it to go? I listened to most of the video but decided not to purchase it since I was already invested in the drug class. But I would like to lock in a sell price for the future.
Hope this helps on what he said for you. Remember, the average 100-year return of the
S&P 500 is 800%. So MindMed has the potential
to triple that in 18 months.
MindMed has the most diversified portfolio of
psychedelic therapeutics we’ve seen to date.
It’s treating a wide range of problems. And it’s
successfully completing clinical trials.
We have a chance to position ourselves in what
could become the juggernaut of psychedelic
medicine. Don’t miss this opportunity.
Wow, thanks, glove77